BioCentury
ARTICLE | Clinical News

Boniva ibandronate regulatory update

February 1, 2016 8:00 AM UTC

Chugai and Taisho said Japan approved a monthly oral formulation of Boniva ibandronate to treat osteoporosis. Japan approved a monthly IV formulation of Boniva in 2013. Chugai partnered with Taisho in 2006 to co-develop and co-market the bisphosphonate that inhibits osteoclast-mediated bone resorption in Japan (see BioCentury, Sept. 18, 2006). ...